학술논문

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
Document Type
article
Source
PLoS pathogens. 19(1)
Subject
Lung
Humans
Cross Reactions
Coinfection
COVID-19
SARS-CoV-2
Pneumonia & Influenza
Biodefense
Immunization
Vaccine Related
Prevention
Emerging Infectious Diseases
Infectious Diseases
Pneumonia
Biotechnology
Aetiology
2.1 Biological and endogenous factors
Infection
Respiratory
Good Health and Well Being
Microbiology
Immunology
Medical Microbiology
Virology
Language
Abstract
The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its sublineages pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available therapies. COVID-19, although targeting primarily the respiratory system, is also now well established that later affects every organ in the body. Most importantly, despite the available therapy and vaccine-elicited protection, the long-term consequences of viral infection in breakthrough and asymptomatic individuals are areas of concern. In the past two years, investigators accumulated evidence on how the virus triggers our immune system and the molecular signals involved in the cross-talk between immune cells and structural cells in the pulmonary vasculature to drive pathological lung complications such as endothelial dysfunction and thrombosis. In the review, we emphasize recent updates on the pathophysiological inflammatory and immune responses associated with SARS-CoV-2 infection and their potential long-term consequences that may consequently lead to the development of pulmonary vascular diseases.